EUVIMEDEUVIMED entdecken
Crossref

L26/O-061 Back to the future: the promise of whole genome sequencing in human embryos

A. Capalbo

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Capalbo.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preimplantation genetic testing (PGT) has evolved substantially over the past three decades, progressing from targeted single-gene assays to genome-wide chromosomal analysis. Yet current clinical practice remains largely indication-specific, with separate strategies for monogenic disorders (PGT-M), structural rearrangements (PGT-SR), and aneuploidy (PGT-A). With advances in sequencing technologies, whole genome sequencing (WGS) of embryo biopsies has emerged as a potential next step—offering a comprehensive genomic assessment within a single unified framework. This presentation explores the potential clinical role of genome sequencing in embryo biopsies, particularly for identifying pathogenic variants associated with embryonic lethality and severe early-onset disease. A significant proportion of implantation failure, early embryonic arrest, and recurrent pregnancy loss is likely attributable to genetic causes that remain undetected with current testing approaches. These may include single-gene defects affecting critical developmental pathways. Importantly, a subset of such variants arise de novo, occurring spontaneously in the embryo and therefore escaping detection through parental carrier screening or preconception investigations. Embryo-based genome sequencing provides a unique opportunity to identify these variants at the earliest developmental stage. Beyond embryonic lethality, genome sequencing may enable detection of pathogenic de novo variants linked to severe neurodevelopmental disorders, where spontaneous mutations represent a major etiological mechanism. Disorders such as intellectual disability, developmental delay, and autism spectrum conditions frequently result from variants absent in the parental genomes. Current PGT strategies are largely blind to this category of risk. Embryonic WGS could therefore address a substantial proportion of genetic disease burden that cannot be mitigated through existing preconception or family-history–based approaches. An additional advantage of genome sequencing is its potential to function as a universal testing platform. In theory, a single comprehensive assay could simultaneously detect single-nucleotide variants, small insertions/deletions, copy number variants, and chromosomal abnormalities. Such integration could streamline laboratory workflows, reduce diagnostic fragmentation, and harmonise testing across PGT indications. However, the promise of embryo genome sequencing must be approached with scientific caution. Before any clinical implementation can be envisaged, rigorous technical validation is essential. Challenges include limited DNA input from trophectoderm biopsies, whole-genome amplification artefacts, allele dropout, coverage variability, detection of mosaicism, and accurate calling of structural variants. Analytical sensitivity, specificity, reproducibility, and uniform genome coverage must be demonstrated at standards equivalent to, or exceeding, those currently applied in clinical genetics. Equally critical is clinical validation. Demonstrating analytical feasibility alone is insufficient. Robust evidence is required to establish the predictive value of detected variants in the embryonic context, particularly for de novo findings. Genotype–phenotype correlations derived from postnatal cohorts may not translate directly to preimplantation embryos. The clinical utility, actionability, psychological impact, and ethical proportionality of reporting specific categories of variants must be carefully evaluated. Prospective studies, long-term follow-up data, and transparent outcome reporting will be indispensable before broad clinical adoption. Ethical and governance frameworks must evolve in parallel, addressing variant interpretation uncertainty, incidental findings, reporting thresholds, and equitable access. Without strong validation and clear clinical indications, premature implementation risks overinterpretation, inequity, and erosion of trust in reproductive medicine. As reproductive genetics stands at a crossroads, the question is not only whether we can sequence the embryo genome, but whether we are prepared to validate, interpret, and govern its results responsibly. Whole genome sequencing holds transformative potential—but its clinical future must be built on robust technical evidence, clinical utility, and ethical clarity.

Zitieren

APA

Capalbo, A. (2026). L26/O-061 Back to the future: the promise of whole genome sequencing in human embryos. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.061

Vancouver

Capalbo A. L26/O-061 Back to the future: the promise of whole genome sequencing in human embryos. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.061

BibTeX
@article{Capalbo2026,
  author = {Capalbo, A.},
  title = {L26/O-061 Back to the future: the promise of whole genome sequencing in human embryos},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.061}
}
Kostenlos starten →